首页> 外文期刊>Archives of pharmacal research >Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.
【24h】

Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.

机译:甲氧氯普胺盐酸盐口服分散型缓释片的研制,开发及性能评价。

获取原文
获取原文并翻译 | 示例
           

摘要

The present study was undertaken to develop and evaluate an oro-dispersible, sustained release tablet of metoclopramide HCl. The technology was comprised of developing sustained release microparticles, and compression of resultant microspheres into a fast dispersible tablet by direct compression. The microspheres of metoclopramide HCl were prepared by an emulsification-solvent evaporation method using ethylcellulose as the matrix polymer. The prepared microspheres were evaluated for morphology, particle size, entrapment efficiency, and in vitro drug release characteristics. Scanning electron microscopy demonstrated spherical particles with a mean diameter of 81.27 +/- 5.87 mum and the drug encapsulation efficiency was found to be 70.15 +/- 3.06%. The process and formulation variables such as rotation speed, polymer concentration, and drug concentration influenced the drug encapsulation efficiency and in vitro drug release. Optimized microspheres were compressed into tablets which were comprised of metoclopramide HCl microspheres, 53% (w/v) of D-mannitol granules, 7% (w/w) of Polyplasdone XL 10, and 0.5% (w/w) of calcium stearate. The tablets demonstrated a hardness of 59 +/- 3 N, friability of 0.21% and disintegration time of 27 +/- 3 sec. The formulations were subjected to stability studies as per ICH guidelines and were found to be stable after a 6 month study. In vivo experiments conducted in rats demonstrated that a constant level of metoclopramide HCl in plasma could be maintained for up to 20 h at a suitable concentration for antiemetic activity. An appropriate combination of excipients made it possible to obtain orally disintegrating sustained release tablets of metoclopramide HCl using simple and conventional techniques.
机译:进行本研究以开发和评估甲氧氯普胺盐酸盐的口腔分散性缓释片剂。该技术包括开发持续释放的微粒,以及通过直接压缩将所得微球压缩成快速分散片剂的方法。用乙基纤维素作为基质聚合物,通过乳化-溶剂蒸发法制备了盐酸甲氯氯吡胺微球。评价所制备的微球的形态,粒径,包封效率和体外药物释放特性。扫描电子显微镜显示球形颗粒的平均直径为81.27 +/-5.87μm,并且发现药物包封效率为70.15 +/- 3.06%。工艺和配方变量(例如转速,聚合物浓度和药物浓度)影响药物封装效率和体外药物释放。将优化的微球压制成片,该片由盐酸甲氯氯普胺微球,53%(w / v)的D-甘露醇颗粒,7%(w / w)的Polyplasdone XL 10和0.5%(w / w)的硬脂酸钙组成。片剂的硬度为59 +/- 3 N,脆性为0.21%,崩解时间为27 +/- 3 sec。根据ICH指南对制剂进行稳定性研究,并在6个月的研究后发现其稳定。在大鼠中进行的体内实验表明,血浆中的甲氧氯普胺HCl的恒定浓度在适当的镇吐活性浓度下可以维持长达20小时。赋形剂的适当组合使得有可能使用简单和常规的技术获得口服崩解的盐酸甲氧氯普胺的缓释片剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号